NCT05836259 - Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 10, 2023

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2032

Conditions

Hypertrophic Cardiomyopathy

Interventions

GENETIC

TN-201

TN-201 is a recombinant adeno-associated virus serotype 9 (AAV9) containing Myosin Binding Protein C (MYBPC3) transgene. It is a single (one-time) intravenous dose.

Trial Locations (10)

19104

WITHDRAWN

Hospital of the University of Pennsylvania, Philadelphia

30322

WITHDRAWN

Emory University, Atlanta

44195

RECRUITING

Cleveland Clinic, Cleveland

45219

WITHDRAWN

The Christ Hospital Physicians - The Ohio Heart and Vascular Center, Cincinnati

55905

RECRUITING

Mayo Clinic, Rochester

77030

RECRUITING

Houston Methodist Hospital, Houston

92093

RECRUITING

UC San Diego Altman Clinical and Translational Research Institute - Center for Clinical Research, La Jolla

94117

RECRUITING

University of California San Francisco, San Francisco

97239

WITHDRAWN

Oregon Health & Science University, Portland

02115

WITHDRAWN

Brigham and Women's Hospital, Boston